Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 28Terminated 19Recruiting 17Active not recruiting 13Unknown 5Not yet recruiting 2Withdrawn 1Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 22Thoracic 2Gastrointestinal 2Breast 2Head & Neck 1Dermatologic 1

Conditions

Melanoma 109Lymphoma, T-Cell, Cutaneous 27Mycosis Fungoides 22Skin Neoplasms 20Sezary Syndrome 19Lymphoma, Non-Hodgkin 16Lymphoma, Follicular 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Neoplasm Metastasis 13Lymphoma, Mantle-Cell 13Lymphoma, Large-Cell, Immunoblastic 13Lymphoma, Large-Cell, Anaplastic 13Lymphoma, Large B-Cell, Diffuse 13Lymphoma, B-Cell, Marginal Zone 13Lymphoma 13Leukemia, Lymphocytic, Chronic, B-Cell 13Burkitt Lymphoma 13Hodgkin Disease 12Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 11Immunoblastic Lymphadenopathy 11Waldenstrom Macroglobulinemia 10Keratosis, Actinic 10Breast Neoplasms 10Uveal Melanoma 9Lymphoma, Extranodal NK-T-Cell 9Leukemia, Myeloid, Acute 9Leukemia, Hairy Cell 9Intraocular Lymphoma 9Carcinoma, Basal Cell 9Neoplasms 8

Interventions

Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Carcinoma, Transitional Cell × Dermatologic × Clear all
NCT05496192 2023-04-14

A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer

Bristol-Myers Squibb

Phase 2 Withdrawn
DermatologicGenitourinary

Carcinoma, Transitional Cell, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡